Resumo

MAYDANA, Mariano et al. Cardiotoxicidad e insuficiencia cardíaca: Experiencias en centros de referencia. Insuf. card. [online]. 2020, vol.15, n.2, pp.28-33. ISSN 1852-3862.

Background. Drug cardiotoxicity and the development of heart failure (HF) is a feared syndrome during the treatment of oncological/oncohematological pathology, mainly with the use of anthracyclines, according to current literature. The frequency of the development of cardiovascular adverse effects with the use of other frequently used drugs, such as monoclonal antibodies, alkylating agents or new therapies such as immune checkpoint inhibitors, is unknown in our population. Objectives. Describe the prevalence of HF in patients treated for oncological/oncohematological pathology. Describe the main cardiovascular adverse effects developed and their possible association with the drugs used. Material and methods. A multicenter analysis was performed from January 2018 to December 2019 at three medical centers in Argentina, and 267 patients were included. Inclusion criteria. Patients over 14 years of age suffering from oncological/oncohematological disease and who were evaluated prior to the start of their treatment. Results. In the follow-up of these patients, 42 of the 267 patients presented cardiovascular adverse effects (15.7%), of which the majority were mild or well tolerated. Mainly observed in 6.4% HF, and in 3% arterial hypertension. Conclusion. A greater number of records of cardiovascular complications associated with cancer treatment are necessary, in order to individualize an early multiparameter evaluation, timely treatment, and correct short and longterm follow-up of each patient.

Palavras-chave : Cardiotoxicity; Heart failure; Adverse effects; Oncological pathology.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )